Variant Peptides CLR RAMP Receptor Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The mechanism of binding of calcitonin gene-related peptide (CGRP) and adrenomedullin (AM) to their respective receptors, specifically how receptor activity-modifying proteins (RAMPs) determine selectivity, has been poorly understood, hindering the development of peptide-based therapeutics with desired selectivity for CGRP or AM receptors.
Innovation Solution
High-resolution crystal structures of CGRP analog-bound CLR:RAMP1 and AM-bound CLR:RAMP2 ECD heterodimers reveal distinct peptide conformations, enabling the formulation of variant peptides that induce antagonistic or enhanced agonistic activity in CLR:RAMP receptor complexes, including variants of AM and CGRP peptides for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptide-based therapeutics are developed targeting CGRP or AM receptors, then therapeutic efficacy for migraine and cardiovascular diseases can be improved, but achieving desired selectivity against CTR and AMY receptors becomes difficult due to overlapping binding mechanisms
Solution Approach 1:
The patent applies local quality by identifying specific amino acid positions in the peptide sequence that are critical for receptor selectivity. By modifying individual residues at key positions (such as positions 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50), the invention creates peptides with tailored binding properties that selectively target CGRP or AM receptors while avoiding CTR and AMY receptors. This localized modification approach allows precise control over receptor interactions.
Solution Approach 2:
The patent employs parameter changes by systematically varying amino acid substitutions, deletions, and modifications at specific positions in the peptide sequence. These parameter changes in peptide structure (charge, hydrophobicity, steric properties) directly affect binding affinity and selectivity for different receptors, enabling the development of therapeutics with optimized selectivity profiles for migraine and cardiovascular indications.
2Loss of information
If the binding mechanism of CGRP and AM to CLR:RAMP receptors is not understood, then rational drug design is hindered, but obtaining high-resolution structural data requires complex crystallographic studies
Solution Approach 1:
The patent applies preliminary action by using molecular dynamics simulations and computational modeling to predict peptide-receptor binding modes and key interaction residues before conducting experimental crystallographic studies. This preliminary computational work guides the design of peptides and selection of crystal forms, reducing the complexity and time required for obtaining high-resolution structural data that reveals the binding mechanism.
Solution Approach 2:
The patent uses computational models and docking simulations as intermediaries to bridge the gap between peptide sequence and receptor binding mechanism. These computational tools provide preliminary insights into binding modes and key residues, serving as mediators that reduce the complexity of direct experimental structural determination and guide rational peptide design for selective receptor targeting.
Data Source
AI summary
Variant peptides of calcitonin gene-related peptide alpha (αCGRP), calcitonin gene-related peptide beta (βCGRP), and adrenomedullin (AM) are disclosed, wherein the variant peptides have high binding affinity and agonistic or antagonistic activity for at least one receptor complex of CLR:RAMP1, CLR:RAMP2, and CLR:RAMP3. Also disclosed are methods of use of the variant peptides in therapeutic treatments.